Search details
1.
Chronic Exposure to Secondary Organic Aerosols Causes Lung Tissue Damage.
Environ Sci Technol
; 57(15): 6085-6094, 2023 04 18.
Article
in English
| MEDLINE | ID: mdl-37014236
2.
Pathogenic Mechanisms of Secondary Organic Aerosols.
Chem Res Toxicol
; 35(7): 1146-1161, 2022 07 18.
Article
in English
| MEDLINE | ID: mdl-35737464
3.
Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
Respir Res
; 22(1): 144, 2021 May 10.
Article
in English
| MEDLINE | ID: mdl-33971856
4.
Management of patients with pulmonary mycobacteriosis in France: a multicenter retrospective cohort study.
BMC Pulm Med
; 21(1): 333, 2021 Oct 26.
Article
in English
| MEDLINE | ID: mdl-34702233
5.
Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme.
Eur Respir J
; 55(6)2020 06.
Article
in English
| MEDLINE | ID: mdl-32241829
6.
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
Allergy
; 74(9): 1716-1726, 2019 09.
Article
in English
| MEDLINE | ID: mdl-31049972
7.
COMET: a multicomponent home-based disease-management programme versus routine care in severe COPD.
Eur Respir J
; 51(1)2018 01.
Article
in English
| MEDLINE | ID: mdl-29326333
8.
Improvement of exertional dyspneoa in patients with chronic obstructive pulmonary disease and severe allergic asthma responding to omalizumab.
Clin Exp Allergy
; 53(12): 1298-1301, 2023 12.
Article
in English
| MEDLINE | ID: mdl-37705326
9.
Neutrophil elastase cleaves epithelial cadherin in acutely injured lung epithelium.
Respir Res
; 17(1): 129, 2016 10 17.
Article
in English
| MEDLINE | ID: mdl-27751187
10.
Unopposed cathepsin G, neutrophil elastase, and proteinase 3 cause severe lung damage and emphysema.
Am J Pathol
; 184(8): 2197-210, 2014 Aug.
Article
in English
| MEDLINE | ID: mdl-24929239
11.
Prescribed therapy for asthma: therapeutic ratios and outcomes.
BMC Fam Pract
; 16: 49, 2015 Apr 14.
Article
in English
| MEDLINE | ID: mdl-25880641
12.
Asthma drug ratios and exacerbations: claims data from universal health coverage systems.
Eur Respir J
; 43(5): 1378-86, 2014 May.
Article
in English
| MEDLINE | ID: mdl-24789951
13.
Exome sequencing and pathogenicity-network analysis of five French families implicate mTOR signalling and autophagy in familial sarcoidosis.
Eur Respir J
; 54(2)2019 08.
Article
in English
| MEDLINE | ID: mdl-31023854
14.
Impact of montelukast on asthma associated with rhinitis, and other triggers and co-morbidities.
J Asthma
; 51(1): 1-17, 2014 Feb.
Article
in English
| MEDLINE | ID: mdl-23834429
15.
Relative exposure to controller therapy and asthma exacerbations: a validation study in community pharmacies.
Pharmacoepidemiol Drug Saf
; 23(9): 958-64, 2014 Sep.
Article
in English
| MEDLINE | ID: mdl-24946177
16.
Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis.
Front Med (Lausanne)
; 11: 1341310, 2024.
Article
in English
| MEDLINE | ID: mdl-38585151
17.
Benralizumab in Severe Eosinophilic Asthma and Chronic Rhinosinusitis with Nasal Polyps: The Real-World, Multi-Country RANS Observational Study.
J Asthma Allergy
; 17: 313-324, 2024.
Article
in English
| MEDLINE | ID: mdl-38595692
18.
Articular manifestations related to anti-interleukin-5 therapies in severe asthma: a case series.
ERJ Open Res
; 10(1)2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38410709
19.
Severe asthma care trajectories: the French RAMSES cohort.
ERJ Open Res
; 10(2)2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38651091
20.
Xolair-induced recurrent anaphylaxis through sensitization to the excipient polysorbate.
Ann Allergy Asthma Immunol
; 120(6): 664-666, 2018 06.
Article
in English
| MEDLINE | ID: mdl-29481891